查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701270

小分子創新 API CDMO 市場規模、佔有率、趨勢分析報告：按階段類型、客戶類型、治療領域、地區和細分市場預測，2025-2030 年

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type (Pharmaceutical, Biotechnology), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

小分子創新者 API CDMO 市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球小分子創新 API CDMO 市場預計到 2030 年將達到 471.4 億美元，2025 年至 2030 年的複合年成長率為 6.38%。

製藥公司外包趨勢的不斷成長、小分子藥物需求的不斷增加以及臨床測試數量的激增預計將對市場產生積極影響。 CDMO 在製藥領域的使用日益增多的原因有很多，其中成本效益是一個突出的因素。外包已成為製藥公司透過避免昂貴的基礎設施和資本支出來降低開支的有效策略。 CDMO 提供必要的專業知識和基礎設施，以財務審慎的方式提供藥物開發和製造服務。

此外，提高效率也是製藥外包的關鍵驅動力。隨著製藥公司面臨越來越大的壓力來迅速將新藥推向市場，外包已成為加速藥物開發過程的解決方案。 CDMO 利用其專業知識、經驗和最先進的設施來促進高品質藥品的快速高效生產，使製藥公司能夠滿足其開發時間表。此外，隨著新型療法和罕見疾病藥物的不斷湧入，以及已通過核准產品的收益不斷提高，製藥公司正在選擇 CDMO 來利用其先進的基礎設施和專業知識。此外，CDMO 的持續技術進步正在提供創新的小分子原料藥，以滿足醫療保健產業對創新、效率和法規遵循日益成長的需求。

公司採用先進技術可以改善藥物開發、製造流程和生產力。製藥業對新型小分子創新 API 的需求不斷增加，促使商業 CDMO 擴大其產能，預計將促進市場成長。例如，2023年8月，Astex宣布與MSD達成研究和授權合約，對含有腫瘤抑制蛋白的小分子化合物候選物進行分類，用於治療癌症。根據協議，該公司將利用其基於片段的藥物發現平台開發化合物，並與默沙東一起列出先導化合物以進行臨床前開發和最佳化。

小分子創新者 API CDMO 市場報告重點

  • 臨床階段類型部分引領小分子創新 API CDMO 產業，佔 2024 年全球收益的 54.56%。預計臨床前部分在預測期內將以良好的複合年成長率成長。
  • 2024 年，製藥業佔據市場主導地位，收益佔有率達 91.07%。近一個世紀以來，小分子藥物一直是製藥業的支柱。生物技術領域的擴張受到生物技術需求的不斷成長和分子效率的提高的推動。
  • 2024 年小分子創新 API CDMO 市場將以腫瘤學領域為主導，預計在預測期內該領域將以 6.80% 最快的複合年成長率成長。感染疾病市場正在見證各個疾病領域的動態趨勢和情景。
  • 預計北美小分子創新 API CDMO 市場在預測期內的複合年成長率為 5.91%。 2024 年，亞太地區佔最大市場佔有率，為 41.74%。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 小分子創新 API CDMO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 科技
    • 小分子創新者 API CDMO 將 AI 融入市場
  • 按階段和地區分類的臨床試驗總數（2021-2024 年）
    • 各階段臨床試驗總數（2021-2024）
    • 各地區臨床試驗總數（2021-2024）
  • 定價模式分析
  • 市場分析工具
    • 波特五大分析
    • PESTEL 與 SWOT 分析
    • COVID-19影響分析

第4章 小分子創新 API CDMO 市場：依階段類型估算與趨勢分析

  • 小分子創新 API CDMO 市場（依階段類型）：細分儀表板
  • 小分子創新 API CDMO 市場（以階段類型）：波動分析
  • 依階段類型，2018-2030
  • 臨床前
  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的

5. 小分子創新 API CDMO 市場（依客戶類型、估計值和趨勢分析）

  • 小分子創新者 API CDMO 市場（按客戶類型）：細分儀表板
  • 小分子創新者 API CDMO 市場（依客戶類型）：變異分析
  • 依客戶類型，2018-2030
  • 製藥
    • 小的
    • 中等的
    • 大的
  • 生物技術
    • 小的
    • 中等的
    • 大的

6. 小分子創新 API CDMO 市場（依治療領域、估價和趨勢分析）

  • 小分子創新 API CDMO 市場（按治療領域）：細分儀表板
  • 小分子創新 API CDMO 市場（依治療領域）：差異分析
  • 依治療領域，2018-2030年
  • 心血管疾病
  • 腫瘤學
  • 呼吸系統疾病
  • 神經病學
  • 代謝紊亂
  • 感染疾病
  • 其他

7. 小分子創新 API CDMO 市場：按地區估算與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 台灣
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 以色列

第8章競爭格局

  • 市場參與企業分類
  • 2024年市場分析（熱圖分析）
  • 公司簡介
    • Lonza Group Ltd.
    • Novo Holdings（Catalent, Inc.）
    • Thermo Fisher Scientific, Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Samsung Biologics
    • Labcorp
    • Ajinomoto Bio-Pharma Services
    • Piramal Pharma Solutions
    • Jubilant Life Sciences（Jubilant Biosys Limited）
    • WuXi AppTec Co., Ltd.
Product Code: GVR-4-68040-250-0

Small Molecule Innovator API CDMO Market Growth & Trends:

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.38% from 2025 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights:

  • The clinical stage type segment led the small molecule innovator API CDMO industry and accounted for 54.56% of global revenue in 2024. The preclinical segment is anticipated to grow at a lucrative CAGR over the forecast period.
  • The pharmaceutical segment dominated the market in 2024, accounting for a revenue share of 91.07%. Small-molecule drugs have been the backbone of the pharmaceutical industry for nearly a century. The biotechnology segment's expansion is driven by rising demand for biotechnology and enhanced molecular efficiency.
  • The oncology segment dominated the small molecule innovator API CDMO market in 2024 and is expected to grow at the fastest CAGR of 6.80% during the forecast period. The infectious diseases market has witnessed dynamic trends and scenarios across various disease segments.
  • North America small molecule innovator API CDMO market is expected to grow at a CAGR of 5.91% over the forecast period. Asia Pacific held the largest market share of 41.74% in 2024.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Stage Type
    • 1.2.2. Customer Type
    • 1.2.3. Therapeutic Area
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for Small Molecule Drugs
      • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
      • 3.2.1.3. Surge In Number of Clinical Trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Changing Scenarios in Developing Economies
  • 3.3. Technological Landscape
    • 3.3.1. Integration of AI in Small Molecule Innovator API CDMO Market
      • 3.3.1.1. Current Dynamics and Future Trends
        • 3.3.1.1.1. Drug Discovery and Design
        • 3.3.1.1.2. AI-Assisted Drug API Synthesis
        • 3.3.1.1.3. Process Optimization
        • 3.3.1.1.4. Supply Chain Management
        • 3.3.1.1.5. Clinical Trial Optimization
        • 3.3.1.1.6. Regulatory Compliance
  • 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2024)
    • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2024)
    • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2024)
      • 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
      • 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
      • 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
      • 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
      • 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
      • 3.4.2.6. Total Number of Clinical Trials by Therapeutic Area (2021 - 2024)
  • 3.5. Pricing Model Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Analysis
    • 3.6.2. PESTEL by SWOT Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

  • 4.1. Small Molecule Innovator API CDMO Market, By Stage Type: Segment Dashboard
  • 4.2. Small Molecule Innovator API CDMO Market, By Stage Type: Movement Analysis
  • 4.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Stage Type, 2018 - 2030
  • 4.4. Preclinical
    • 4.4.1. Preclinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Clinical
    • 4.5.1. Clinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Phase I
      • 4.5.2.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Phase II
      • 4.5.3.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Phase III
      • 4.5.4.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Commercial
    • 4.6.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

  • 5.1. Small Molecule Innovator API CDMO Market, By Customer Type: Segment Dashboard
  • 5.2. Small Molecule Innovator API CDMO Market, By Customer Type: Movement Analysis
  • 5.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Customer Type, 2018 - 2030
  • 5.4. Pharmaceutical
    • 5.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Small
      • 5.4.2.1. Small Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Medium
      • 5.4.3.1. Medium Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Large
      • 5.4.4.1. Large Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biotechnology
    • 5.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Small
      • 5.5.2.1. Small Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Medium
      • 5.5.3.1. Medium Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. Large
      • 5.5.4.1. Large Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Segment Dashboard
  • 6.2. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Movement Analysis
  • 6.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Oncology
    • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Respiratory Disorders
    • 6.6.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Neurology
    • 6.7.1. Neurology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Metabolic Disorders
    • 6.8.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Infectious Diseases
    • 6.9.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Taiwan
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Framework
      • 7.6.8.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.6. Israel
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Lonza Group Ltd.
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Novo Holdings (Catalent, Inc.)
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Thermo Fisher Scientific, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Siegfried Holding AG
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Recipharm AB
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. CordenPharma International
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Samsung Biologics
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Labcorp
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Ajinomoto Bio-Pharma Services
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Piramal Pharma Solutions
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. WuXi AppTec Co., Ltd.
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 5 Global Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 6 Global Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 7 Global Small Molecule Innovator API CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 10 North America Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 11 North America Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 12 U.S. Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 15 Canada Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 18 Mexico Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 19 Mexico Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 21 Europe Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 25 UK Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 26 UK Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 27 UK Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 28 Germany Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 29 Germany Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 31 France Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 32 France Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 33 France Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 34 Italy Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 35 Italy Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 37 Spain Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 38 Spain Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 40 Denmark Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 41 Denmark Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 43 Sweden Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 44 Sweden Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 46 Norway Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 47 Norway Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 48 Norway Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 53 China Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 54 China Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 55 China Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 56 Japan Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 57 Japan Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 58 Japan Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 59 India Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 60 India Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 61 India Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 62 Australia Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 64 Australia Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 65 South Korea Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 66 South Korea Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 67 South Korea Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 68 Thailand Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 69 Thailand Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 70 Thailand Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 71 Taiwan Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 72 Taiwan Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 73 Taiwan Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 74 Latin America Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 75 Latin America Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 76 Latin America Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 77 Latin America Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 78 Brazil Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 79 Brazil Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 80 Brazil Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 81 Argentina Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 82 Argentina Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 83 Argentina Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 87 Middle East & Africa Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 88 South Africa Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 90 South Africa Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 94 UAE Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 95 UAE Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 96 UAE Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 98 Kuwait Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 99 Kuwait Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 100 Israel Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 101 Israel Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 102 Israel Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Small molecule innovator API CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot 1
  • Fig. 13 Segment snapshot 2
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market outlook, 2024 (USD Million)
  • Fig. 16 Ancillary market outlook, 2024 (USD Million)
  • Fig. 17 Small Molecule Innovator API CDMO Market Dynamics
  • Fig. 18 Percentage of clinical trials by major countries in North America
  • Fig. 19 Percentage of clinical trials by major countries in Europe
  • Fig. 20 Percentage of clinical trials by major countries in Asia Pacific
  • Fig. 21 Percentage of clinical trials by major countries in Latin America
  • Fig. 22 Percentage of clinical trials by major countries in Middle East & Africa
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 Small molecule innovator API CDMO market: PESTEL analysis
  • Fig. 25 Small Molecule Innovator API CDMO Market: Stage Type outlook and key takeaways
  • Fig. 26 Small Molecule Innovator API CDMO Market: Stage Type movement analysis
  • Fig. 27 Preclinical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Clinical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Commercial market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Small Molecule Innovator API CDMO Market: Customer Type outlook and key takeaways
  • Fig. 34 Small Molecule Innovator API CDMO Market: Customer Type movement analysis
  • Fig. 35 Pharmaceutical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Small market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Medium market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Large market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Biotechnology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Small market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Medium market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Large market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Small Molecule Innovator API CDMO Market: Therapeutic Area outlook and key takeaways
  • Fig. 44 Small Molecule Innovator API CDMO Market: Therapeutic Area movement analysis
  • Fig. 45 Cardiovascular Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Respiratory Disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Metabolic Disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Infectious Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Regional Marketplace: Key Takeaways
  • Fig. 53 North America Small Molecule Innovator API CDMO Market estimates and forecasts, 2018-2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 U.S. Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Canada Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Mexico Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Europe Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 UK Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Germany Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 France Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Italy Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Spain Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Denmark outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Sweden outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Norway outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Asia Pacific Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 China Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Japan Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 India Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Australia Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Korea Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Thailand Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Taiwan Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Latin America Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Brazil Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Argentina Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 MEA Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 South Africa Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Fig. Key country dynamics
  • Fig. 101 Saudi Arabia Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 UAE Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Kuwait Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Israel Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key company categorization
  • Fig. 109 Service heat map analysis
  • Fig. 110 Strategic framework